ACGN — Aceragen Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $3.20m
- $1.08m
- $4.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.24 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -72.97% | ||
| Return on Equity | -169.66% | ||
| Operating Margin | -603.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.66 | 1.45 | n/a | n/a | 4.86 | n/a | n/a | 40.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aceragen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.
Directors
- James Geraghty NEC (67)
- Vincent Milano PRE (57)
- John Kirby CFO (49)
- Daniel Soland COO (63)
- Bryant Lim SVP (50)
- Cristina Csimma IND (62)
- Michael Dougherty IND (63)
- Mark Goldberg IND (67)
- Maxine Gowen IND (62)
- Carol Schafer IND (57)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- August 24th, 2005
- Public Since
- January 25th, 1996
- No. of Shareholders
- 27
- No. of Employees
- 26
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 8,420,276
- Address
- 505 Eagleview Boulevard, Suite 212, EXTON, 19341
- Web
- https://www.aceragen.com/
- Phone
- +1 4843481600
- Auditors
- Ernst & Young LLP
Upcoming Events for ACGN
Aceragen Inc Extraordinary Shareholders Meeting
Q3 2023 Aceragen Inc Earnings Release
Similar to ACGN
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acer Therapeutics
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Aceragen share price?
As of Today at 13:00 UTC, shares in Aceragen are trading at $0.63. This share price information is delayed by 15 minutes.
How has the Aceragen share price performed this year?
Shares in Aceragen last closed at $0.63 and the price had moved by -91.01% over the past 365 days. In terms of relative price strength the Aceragen share price has underperformed the S&P500 Index by -92.28% over the past year.
What are the analyst and broker recommendations for Aceragen?
The overall consensus recommendation for Aceragen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aceragen dividend yield?
Aceragen does not currently pay a dividend.
Does Aceragen pay a dividend?
Aceragen does not currently pay a dividend.
When does Aceragen next pay dividends?
Aceragen does not currently pay a dividend.
How do I buy Aceragen shares?
To buy shares in Aceragen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aceragen?
As of the previous close price of $0.63, shares in Aceragen had a market capitalisation of $7.54m.
Where are Aceragen shares listed?
Here are the trading details for Aceragen:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ACGN
What kind of share is Aceragen?
Based on an overall assessment of its quality, value and momentum Aceragen is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aceragen share price forecast for 2023?
The analyst consensus target price for shares in Aceragen is $11.97. That is 1799.44% above the last closing price of $0.63.
Analysts covering Aceragen currently have a consensus Earnings Per Share (EPS) forecast of -$2.18 for the next financial year.
Find out moreWhat is the trend in the Aceragen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aceragen. Over the past six months, its share price has underperformed the S&P500 Index by -88.42%.
As of the last closing price of $0.63, shares in Aceragen were trading -84.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aceragen PE Ratio?
The Aceragen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.63.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aceragen?
Aceragen's management team is headed by:
- James Geraghty - NEC
- Vincent Milano - PRE
- John Kirby - CFO
- Daniel Soland - COO
- Bryant Lim - SVP
- Cristina Csimma - IND
- Michael Dougherty - IND
- Mark Goldberg - IND
- Maxine Gowen - IND
- Carol Schafer - IND